John A. Orwin

This profile gathers the share dealings of John A. Orwin across 7 companies, led by Seagen Inc., Travere Therapeutics, Inc. and Anaptysbio, Inc. Over a trading history stretching from 12 February 2016 to 15 September 2026, the count stands at 42 filings.

Both buying and selling appear: 3 purchases worth €119k, against 2 sales worth €45k. Taken together, the purchases exceed the sales by €74k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 22 share grants and 10 option exercises.

In size, the median ticket on the buying side is €50k. 1 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

Most recently, on 17 September 2026, the filings show an option exercise in First Tracks Biotherapeutics, Inc. The last insider purchase was made public on 17 April 2024, 917 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.